Copper-64 DOTA AE105 - Curasight
Alternative Names: 64Cu-DOTA-AE105Latest Information Update: 19 Jul 2024
At a glance
- Originator Curasight
- Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 01 Jun 2024 Phase-II clinical trials in Prostate cancer (Diagnosis) in Denmark (Parenteral) (NCT06474806)
- 16 Apr 2024 EMA approves CTA application for phase II trial for Copper-64 DOTA AE105 in Prostate cancer (Curasight website, July 2024)